Hypersensitivity and desensitization to darunavir in a case of HIV infection with triple-class drug resistance: Case description and review of the literature

Journal of the International Association of Providers of AIDS Care

Volumn 12, Issue 6, 2013, Pages 378-379

  Lorber, Margalit ^a   Haddad, Salim ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

antiretroviral therapy; darunavir; hypersensitivity reaction

Indexed keywords

ANTIHISTAMINIC AGENT; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; INDINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; RALTEGRAVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; CASE REPORT; CD4 LYMPHOCYTE COUNT; DESENSITIZATION; DRUG ERUPTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; VIRUS LOAD;

EID: 84887879621     PISSN: 23259574     EISSN: 23259582     Source Type: Journal    
DOI: 10.1177/2325957413488189     Document Type: Review

References (13)

1. Busse KH, Penzak SR. Darunavir: a second-generation protease inhibitor. Am J Health Syst Pharm. 2007 ; 64 (15). 1593-1602
2. Tibotec. PREZISTA (Darunavir) summary of product characteristics. http://www.emea.europa.eu/humandocs/PDFs/EPAR/prezista/H-707-PI-en.pdf. Accessed July 2, 2008.
3. Marcos MC, Ocampo A, Moreno E. Hypersensitivity reactions to antiretroviral agents in HIV-infected patients. Med Clin (Barc). 2007 ; 128 (2). 61-69
4. Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol. 2011 ; 71 (5). 659-671
5. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007 ; 369 (9568). 1169-1178
6. Phillips EJ, Knowles SR. Comment: sulfonamide cross-reactivity: fact or fiction?. Ann Pharmacother. 2005 ; 39 (7-8). 1372-1373
7. Arasteh K, Yeni P, Pozniak A, et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther. 2009 ; 14 (6). 859-864
8. Kohli-Pamnani A, Huynh P, Lobo F. Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus. Ann Allergy Asthma Immunol. 2006 ; 96 (4). 620-623
9. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007 ; 370 (9581). 49-58
10. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr. 2007 ; 46 (1). 24-31
11. Prezista [package insert]. Titusville, NJ: Tibotec Therapeutics; 2006.
12. Marcos Bravo MC, Ocampo Hermida A, Martínez Vilela J, et al. Hypersensitivity reaction to darunavir and desensitization protocol. J Investig Allergol Clin Immunol. 2009 ; 19 (3). 237-252
13. Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother. 2008 ; 62 (5). 879-888